Results for tag: "Fidaxomicin"

Fidaxomicin is an antibiotic used to treat Clostridium difficile infection (CDI). It is a macrocyclic antibiotic that works by inhibiting bacterial protein synthesis. Fidaxomicin is the only antibiotic approved by the US Food and Drug Administration (FDA) for the treatment of CDI. It is also approved in Europe and other countries. Fidaxomicin has been shown to be more effective than vancomycin, the standard of care for CDI, in reducing recurrence of CDI. It is also associated with fewer side effects than vancomycin. Fidaxomicin is marketed by Merck & Co. under the brand name Dificid. Other companies involved in the fidaxomicin market include AstraZeneca, Pfizer, and Cubist Pharmaceuticals. Show Less Read more